SecBot SecBot

ANIP

ANI PHARMACEUTICALS INC
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001023024 Biotech & Drug Discovery
$68.55 −0.58 (−0.84%)
Nov 20 4:00 PM ET · prev $69.13
Market cap
$1.6B
Small cap
Consensus
Buy
80% Buy or better · 15 analysts
Median target
$102.00
+49% · range $85.00–121.00
1 year
−14.0%
from $79.72 · Nov 21
30 days
−5.1%
from $72.24
52-week range
$67.41–86.03
−20% from high · low Nov 6
Avg volume 20D
486.4K
Nov 5 spike 1.30M
Short interest
3.58M
≈15.8% of shares · +3.2%
Days to cover
11.9
at average volume
Insider net
−$11.8M
0 buyers · 10 sellers · since Mar 3
New fund stakes
0
Q3 2026 13F · 1 exit
Filing reports
28
analyzed by SecBot
SecBot read BULLISH 16 reports · 90 days
Balance 1 bearish · 5 bullish · 1 mixed · 9 neutral oldest → newest, height = score
Avg score ·High conf. 12/16

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

  • May 11 to May 13 ▼ 3 days of insider sells: $5.7M by 5 insiders, avg $78.25
  • Jun 5 to Jun 12 ▼ 3 days of insider sells: $467.7K by 3 insiders, avg $80.48
  • Jun 29 to Jul 2 ▼ 2 days of insider sells: $524.7K by 1 insider, avg $85.13
  • Aug 10 to Aug 13 ▼ 2 days of insider sells: $281.2K by 2 insiders, avg $76.79
  • Aug 25 to Aug 31 ▼ 2 days of insider sells: $608.7K by 2 insiders, avg $73.78
  • Sep 11 to Sep 15 ▼ 3 days of insider sells: $490.3K by 3 insiders, avg $71.06
  • Sep 23 Contract: ANI Pharmaceuticals Announces the FDA Approval of Everolim…
  • Sep 23 Oppenheimer initiates
  • Sep 30 ▼ Short interest jumps 40.2% to 3.49M
  • Oct 13 to Oct 15 ▼ 2 days of insider sells: $425.0K by 2 insiders, avg $72.03
  • Nov 5 ▲ ANI Pharmaceuticals reported Q3 2026 revenue of $290.8M (+27.6% YoY)…
  • Nov 13 to Nov 18 ▼ 3 days of insider sells: $420.0K by 2 insiders, avg $71.18

Signal stack

Where each data set points today.

  • InsidersBEARISH

    10 insiders sold $11.8M.

  • InstitutionsMIXED

    Q3 2026: 23 added (0 new), 33 trimmed or exited.

  • AnalystsBULLISH

    12 of 15 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate $2.853 → $2.559 over 90 days. 0 up, 5 down in 30 days.

  • Short sellersSTEADY

    Short interest +3.2% to 3.58M shares. 11.9 days to cover, ≈15.8% of shares.

  • TrendDOWNTREND

    5% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
1
exit
FundMoveSharesValue
AMERICAN CENTURY COMPANIES INCADD912,647$66.3M
UBS Group AGDOUBLED621,335$45.1M
VICTORY CAPITAL MANAGEMENT INCDOUBLED345,504$25.1M
MILLENNIUM MANAGEMENT LLCTRIM243,146$17.7M
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLCDOUBLED204,017$14.8M
SUSQUEHANNA INTERNATIONAL GROUP, LLPDOUBLED169,229$12.3M
Schonfeld Strategic Advisors LLCDOUBLED133,279$9.7M
Man Group plcADD112,362$8.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 80% rate it Buy or better
Strong Buy5Buy7Hold3Sell0Strong Sell0
12-month targets · 8 analysts

Price is below the lowest target. Median implies +49%.Targets as of Nov 22, 2026.

Recent actions
DateFirmActionRating
Nov 6, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Sep 23, 2026Oppenheimer
INITIATE
INITIATEPerform
Aug 10, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Aug 10, 2026Canaccord Genuity
MAINTAIN
MAINTAINHold
Jul 17, 2026Canaccord Genuity
INITIATE
INITIATEHold
Jul 10, 2026Guggenheim
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$11.8M
sold · 10 insiders
DateInsiderTypeValue
Nov 18, 2026
Lalwani Nikhil
PRESIDENT & CEO
Nov 18, 2026
SELL$290.5K
Nov 16, 2026
Lalwani Nikhil
PRESIDENT & CEO
Nov 16, 2026
SELL$94.1K
Nov 13, 2026
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
Nov 13, 2026
SELL$35.4K
Oct 29, 2026
CAREY STEPHEN P.
SVP & CFO
Oct 29, 2026
SELL$207.7K
Oct 15, 2026
Lalwani Nikhil
PRESIDENT & CEO
Oct 15, 2026
SELL$388.2K
Oct 13, 2026
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
Oct 13, 2026
SELL$36.8K
Sep 29, 2026
CAREY STEPHEN P.
SVP & CFO
Sep 29, 2026
SELL$208.1K
Sep 15, 2026
Lalwani Nikhil
PRESIDENT & CEO
Sep 15, 2026
SELL$383.4K

Earnings setup

Estimates
$2.56
EPS estimate, this quarter
−10%
estimate change, 90 days
0↑ 5↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$2.56$2.41–$2.66-9.2%$305.3M
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
3,583,674
shares short
+3.2%
vs prior settlement
11.9
days to cover
≈15.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 19, 2026 Other
ANI Pharmaceuticals to Present at Upcoming December Investor Conference
PRINCETON, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or
Nov 18, 2026 SEC
CEO Nikhil Lalwani and SVP Meredith Cook sold shares totaling $130K in open-market transactions under 10b5-1 plans…
CLUSTER · Impact 2/10
Nov 18, 2026 Insider
Lalwani Nikhil sold 4,082 shares
PRESIDENT & CEO @ $71.16 ($290.5K)
Nov 16, 2026 SEC
CEO Nikhil Lalwani filed a Form 144 notice to sell 5,400 shares of ANI Pharmaceuticals common stock, with an estimated…
144 · Impact 2/10
Nov 16, 2026 SEC
ANI Pharmaceuticals published an updated November 2026 investor presentation reaffirming its 2026 financial guidance…
8-K · Impact 3/10
Nov 16, 2026 Insider
Lalwani Nikhil sold 1,318 shares
PRESIDENT & CEO @ $71.40 ($94.1K)
Nov 13, 2026 Insider
Cook Meredith sold 500 shares
SR. VP, GENERAL COUNSEL & SEC. @ $70.80 ($35.4K)
Nov 5, 2026 Press
ANI Pharmaceuticals announced a recommended public offer to acquire Egetis Therapeutics for SEK 11.25 per share…
Impact 6/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent

SecBot reports

28 filings · 6 press releases · 6 bullish · 3 bearish · 1 mixed · 18 neutral
All ANIP filing & press-release reports (34)